Cargando…

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors

The sodium-glucose cotransporter-2 (SGLT2) is expressed on the luminal side of proximal tubule epithelial cells in the kidney. While pharmacological inhibition of SGLT2 provides kidney protection in diabetic kidney disease (DKD), the molecular mechanisms remain unclear. In this issue of the JCI, Sch...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tuttle, Katherine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974093/ https://www.ncbi.nlm.nih.gov/pubmed/36856116 http://dx.doi.org/10.1172/JCI167700

Ejemplares similares

Class effect for SGLT-2 inhibitors: a tale of 9 drugs
por: Giugliano, Dario, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 (SGLT-2) inhibition and kidney protection: Does improvement in kidney hypoxia play a role?
por: Burnier, Michel
Publicado: (2021)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

An evolutionary perspective on cell migration: Digging for the roots of amoeboid motility
por: Titus, Margaret A., et al.
Publicado: (2017)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney
por: Tuttle, Katherine R.
Publicado: (2017)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
por: Giugliano, Dario, et al.
Publicado: (2020)

Digging into the HLA pockets: A new association with acute leukaemias
por: Gurnari, Carmelo, et al.
Publicado: (2022)

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
por: Potier, Louis, et al.
Publicado: (2021)

Digging Deeper Into Hepatitis C Virus Outbreaks
por: Olmstead, Andrea D.
Publicado: (2016)

Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney
por: Tuttle, Katherine R., et al.
Publicado: (2021)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

Digging deep in the High Tatras mountains
Publicado: (2004)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

Lis1 finds new digs on the desmosome
por: Leslie, Mitch
Publicado: (2011)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

UK digs deep in dark matter race
Publicado: (2008)

CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis
por: Dursi, L. Jonathan, et al.
Publicado: (2021)

A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
por: Kim, Sun H., et al.
Publicado: (2020)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
por: Packer, Milton
Publicado: (2019)

Digging deep into “dirty” drugs – modulation of the methylation machinery
por: Pleyer, Lisa, et al.
Publicado: (2015)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
por: Scheen, A.J.
Publicado: (2020)

Structural mechanism of SGLT1 inhibitors
por: Niu, Yange, et al.
Publicado: (2022)

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
por: Vasquez-Rios, George, et al.
Publicado: (2020)

Digging for development
Publicado: (1994)

The Woman at the Dig
por: Dangel, Leo
Publicado: (2004)

Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
por: Evans, Marc
Publicado: (2018)

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
por: Margonato, Davide, et al.
Publicado: (2020)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
por: Elrakaybi, Asmaa, et al.
Publicado: (2022)

A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets
por: Hodson, David J., et al.
Publicado: (2020)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c5eh7m4a4me4cq183jgmpofpf8